The authors reply

New England Journal of Medicine

Volumn 373, Issue 13, 2015, Pages 1270-1271

  Larkin, James ^a   Hodi, F Stephen ^b   Wolchok, Jedd D ^c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; NIVOLUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LETTER; MELANOMA; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; FEMALE; MALE; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MELANOMA; SKIN NEOPLASMS;

EID: 84942089321     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1509660     Document Type: Letter

References (1)

1. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006-17.